Voyager Therapeutics - VYGR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)

This chart shows the closing price for VYGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Voyager Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYGR

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for VYGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Voyager Therapeutics. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/7/2021BTIG ResearchLower TargetBuy$31.00
8/3/2021Fundamental ResearchReiterated RatingBuy$32.00
7/28/2021Eight CapitalInitiated CoverageBuy$31.00
6/30/2021Fundamental ResearchInitiated CoverageTop Pick$32.08
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Voyager Therapeutics logo
Voyager Digital Ltd., through its subsidiaries, engages in the development and commercialization of a digital platform that enables users to buy and sell digital assets (cryptocurrencies) across multiple exchanges in one account primarily in the United States and Canada. The company was founded in 2018 and is headquartered in New York, New York.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

The following Wall Street analysts have issued reports on Voyager Therapeutics in the last twelve months:
View the latest analyst ratings for VYGR.

What is the current price target for Voyager Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Voyager Therapeutics in the next year.
View the latest price targets for VYGR.

What is the current consensus analyst rating for Voyager Therapeutics?

Voyager Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VYGR.

What other companies compete with Voyager Therapeutics?

How do I contact Voyager Therapeutics' investor relations team?

Voyager Therapeutics' physical mailing address is 75 Sidney St, Cambridge, Massachusetts 02139-4134. The company's listed phone number is 212 547 8807. The official website for Voyager Therapeutics is www.investvoyager.com. Learn More about contacing Voyager Therapeutics investor relations.